Last reviewed · How we verify
Abilify
At a glance
| Generic name | Abilify |
|---|---|
| Also known as | abilify is a generic name of aripiprazole |
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Target | 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Agitation associated with Bipolar Mania
- Agitation associated with Schizophrenia
- Bipolar affective disorder, current episode manic
- Bipolar disorder in remission
- Depression Treatment Adjunct
- Infantile autism
- Mixed bipolar I disorder
- Schizophrenia
Common side effects
- Increased weight
- Akathisia
- Injection site pain
- Sedation
Key clinical trials
- Substance Misuse To Psychosis for Stimulants (PHASE2, PHASE3)
- Cerebellum-based Imaging Neural Markers for Antipsychotic Response
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
- Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole (PHASE4)
- Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. (PHASE4)
- C-Cog in Early Course Schizophrenia Study (PHASE4)
- Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia (PHASE3)
- Enhancing Recovery in Early Schizophrenia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Abilify CI brief — competitive landscape report
- Abilify updates RSS · CI watch RSS
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. portfolio CI